About eGenesis
eGenesis is a company based in Cambridge (United States) founded in 2015 by George M Church. eGenesis has raised $481.42 million across 7 funding rounds from investors including Bayer, ARE and DaVita. The company has 94 employees as of December 31, 2022. eGenesis has completed 1 acquisition, including ICBiotec. eGenesis offers products and services including EGEN Platform and HuCo Organs. eGenesis operates in a competitive market with competitors including Beam Therapeutics, Korro Bio, Metagenomi, Prime Medicine and Scribe Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 94 as on 31 Dec, 2022
- Founders George M Church
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Egenesis, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of eGenesis
eGenesis offers a comprehensive portfolio of products and services, including EGEN Platform and HuCo Organs.
Tool for engineering organs to overcome xenotransplantation barriers.
Genetically modified porcine organs for human compatibility.
People of eGenesis
Unlock access to complete
Unlock access to complete
Funding Insights of eGenesis
eGenesis has successfully raised a total of $481.42M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $191 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in eGenesis
eGenesis has secured backing from 28 investors, including institutional and venture fund investors. Prominent investors backing the company include Bayer, ARE and DaVita.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage technology companies are funded by Lux Capital.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Early-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for eGenesis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by eGenesis
eGenesis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ICBiotec.
Investment portfolio details for eGenesis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of gene editing platform for the development of human-compatible organs, tissues and cells
|
Locked | Locked | 1998 | Locked |
Complete acquisition details for eGenesis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - eGenesis
Detailed financials for eGenesis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Egenesis Comparisons
Peer comparison for eGenesis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of eGenesis
eGenesis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, Korro Bio, Metagenomi, Prime Medicine and Scribe Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Next-generation gene editing tools are developed for drug enhancement.
|
|
| Locked | Locked | Locked |
Genetic therapies for diseases are developed using prime editing technology.
|
|
| Locked | Locked | Locked |
A CRISPR-based gene-editing platform is developed for therapeutic applications.
|
Detailed competitors of eGenesis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Egenesis
Complete news archive for eGenesis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about eGenesis
eGenesis was founded in 2015 and raised its 1st funding round 1 year after it was founded.
eGenesis is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Michael Curtis is the current CEO of eGenesis.
eGenesis is a funded company, having raised a total of $481.42M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at eGenesis is 94.
eGenesis was founded in 2015 and is based in Cambridge, United States. Operations focus on the biotechnology sector, where a gene transplantation platform is utilized to humanize pig cells for producing human-compatible organs. This technology relies on next-generation genome engineering and CRISPR tools. Organs grown in donor pigs are harvested for safe transplantation into human patients, addressing needs in organ transplantation.
eGenesis's top competitors include Tessera Therapeutics, Korro Bio and Beam Therapeutics.
eGenesis offers EGEN Platform and HuCo Organs.
eGenesis has made 1 acquisition, including ICBiotec.
eGenesis has 28 investors. Key investors include Bayer, ARE, DaVita, Natco Pharma, and Khosla Ventures.